224 related articles for article (PubMed ID: 31912789)
1. Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.
Ugurel S; Schadendorf D; Horny K; Sucker A; Schramm S; Utikal J; Pföhler C; Herbst R; Schilling B; Blank C; Becker JC; Paschen A; Zimmer L; Livingstone E; Horn PA; Rebmann V
Ann Oncol; 2020 Jan; 31(1):144-152. PubMed ID: 31912789
[TBL] [Abstract][Full Text] [Related]
2. Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM.
Placke JM; Kimmig M; Griewank K; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Welzel J; Engel DR; Kreft S; Sucker A; Lodde G; Krefting F; Stoffels I; Klode J; Roesch A; Zimmer L; Livingstone E; Hadaschik E; Becker JC; Weichenthal M; Tasdogan A; Schadendorf D; Ugurel S
EBioMedicine; 2023 Oct; 96():104774. PubMed ID: 37660535
[TBL] [Abstract][Full Text] [Related]
3. Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma.
Placke JM; Soun C; Bottek J; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Pfeiffer C; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Zimmer L; Livingstone E; Becker JC; Lodde G; Sucker A; Griewank K; Horn S; Hadaschik E; Roesch A; Schadendorf D; Engel DR; Ugurel S
Front Oncol; 2021; 11():741993. PubMed ID: 34621681
[TBL] [Abstract][Full Text] [Related]
4. Soluble PD-L1 predicts tumor response and immune-related adverse events in patients with advanced melanoma treated with anti-PD-1 antibodies.
Oya K; Nakamura Y; Shen LT; Ishizuki S; Matsusaka S; Fujisawa Y
J Dermatol; 2024 Jun; 51(6):807-815. PubMed ID: 38433350
[TBL] [Abstract][Full Text] [Related]
5. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Serratì S; Guida M; Di Fonte R; De Summa S; Strippoli S; Iacobazzi RM; Quarta A; De Risi I; Guida G; Paradiso A; Porcelli L; Azzariti A
Mol Cancer; 2022 Jan; 21(1):20. PubMed ID: 35042524
[TBL] [Abstract][Full Text] [Related]
6. A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma.
Girault I; Adam J; Shen S; Roy S; Brard C; Faouzi S; Routier E; Lupu J; Warren S; Sorg K; Ong S; Morel P; Scoazec JY; Vagner S; Robert C
Clin Cancer Res; 2022 Feb; 28(3):518-525. PubMed ID: 34785583
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
[TBL] [Abstract][Full Text] [Related]
8. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
[TBL] [Abstract][Full Text] [Related]
9. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
10. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Daud AI; Wolchok JD; Robert C; Hwu WJ; Weber JS; Ribas A; Hodi FS; Joshua AM; Kefford R; Hersey P; Joseph R; Gangadhar TC; Dronca R; Patnaik A; Zarour H; Roach C; Toland G; Lunceford JK; Li XN; Emancipator K; Dolled-Filhart M; Kang SP; Ebbinghaus S; Hamid O
J Clin Oncol; 2016 Dec; 34(34):4102-4109. PubMed ID: 27863197
[TBL] [Abstract][Full Text] [Related]
11. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
12. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
[TBL] [Abstract][Full Text] [Related]
13. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
14. Serum cytokines and creatinine/cystatin C ratio as prognostic biomarkers in advanced cancer patients treated with anti-PD-1/PD-L1 therapy.
Jin SX; Liu BN; Ji HJ; Wu JR; Li BL; Gao XL; Li N; Zheng ZD; Du C
Support Care Cancer; 2024 May; 32(6):370. PubMed ID: 38776028
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
Johnson DB; Bordeaux J; Kim JY; Vaupel C; Rimm DL; Ho TH; Joseph RW; Daud AI; Conry RM; Gaughan EM; Hernandez-Aya LF; Dimou A; Funchain P; Smithy J; Witte JS; McKee SB; Ko J; Wrangle JM; Dabbas B; Tangri S; Lameh J; Hall J; Markowitz J; Balko JM; Dakappagari N
Clin Cancer Res; 2018 Nov; 24(21):5250-5260. PubMed ID: 30021908
[No Abstract] [Full Text] [Related]
16. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
17. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
[TBL] [Abstract][Full Text] [Related]
18. Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial.
Moku P; Shepherd L; Ali SM; Leitzel K; Parulekar WR; Zhu L; Virk S; Nomikos D; Aparicio S; Gelmon K; Drabick J; Cream L; Halstead ES; Umstead TM; Mckeone D; Polimera H; Maddukuri A; Ali A; Nagabhairu V; Poulose J; Pancholy N; Spiegel H; Chen BE; Lipton A
Cancer; 2020 Nov; 126(22):4859-4866. PubMed ID: 32910476
[TBL] [Abstract][Full Text] [Related]
19. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
Turiello R; Capone M; Giannarelli D; Morretta E; Monti MC; Madonna G; Mallardo D; Festino L; Azzaro R; Levesque MP; Imhof L; Weide B; Amaral T; Chevrier M; Sucker A; Rutkowski P; Schadendorf D; Lebbe C; Luke JJ; Wistuba-Hamprecht K; Dummer R; Pinto A; Morello S; Ascierto PA
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361405
[TBL] [Abstract][Full Text] [Related]
20. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]